308430
CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clin… Read more
308430 (308430) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.050x
Based on the latest financial reports, 308430 (308430) has a cash flow conversion efficiency ratio of -0.050x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.40 Billion) by net assets (₩28.14 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
308430 - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how 308430's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
308430 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 308430 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Tong Ren Tang Chinese Medicine Company Limited
PINK:BJTRF
|
0.007x |
|
Westwing Group AG
F:WEW
|
0.221x |
|
Xuchang Ketop Testing Research Ins
SHE:003008
|
0.026x |
|
Designer Brands Inc
NYSE:DBI
|
0.220x |
|
Guangdong Yantang Dairy Co Ltd
SHE:002732
|
0.037x |
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
-0.001x |
|
Washington Real Estate Investment Trust
F:WRI
|
0.018x |
|
Mega-info Media Co.Ltd.
SHE:301102
|
N/A |
Annual Cash Flow Conversion Efficiency for 308430 (2022–2024)
The table below shows the annual cash flow conversion efficiency of 308430 from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩29.58 Billion | ₩-4.78 Billion | -0.162x | +69.23% |
| 2023-12-31 | ₩7.50 Billion | ₩-3.94 Billion | -0.525x | +69.02% |
| 2022-12-31 | ₩2.74 Billion | ₩-4.64 Billion | -1.695x | -- |